Kramer M H, Lobel H O
Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Diseases Control and Prevention, Atlanta, Georgia 30341, USA.
Paediatr Drugs. 2001;3(2):113-21. doi: 10.2165/00128072-200103020-00004.
The evolving patterns of drug resistance in malaria parasites and changes in recommendations for malaria prevention present a challenge to physicians who advise travellers on chemoprophylaxis. Because compliance with personal protection measures is usually low, children should receive appropriate chemoprophylaxis, including breast-fed infants who are not protected through maternal chemoprophylaxis. For travel to areas where chloroquine resistance has not yet been reported (i.e. parts of Central America, the Caribbean and parts of the Middle East), chloroquine alone is sufficient for antimalarial prophylaxis. Mefloquine is the drug of choice for chemoprophylaxis in areas with chloroquine-resistant Plasmodium falciparum, and can be given to infants and young children. The combination of chloroquine and proguanil is well tolerated in children but is much less effective against drug-resistant malaria. Further research is needed to determine the best dosage regimen for antimalarial drugs used for chemoprophylaxis in children.
疟原虫耐药性的不断演变模式以及疟疾预防建议的变化给为旅行者提供化学预防建议的医生带来了挑战。由于个人防护措施的依从性通常较低,儿童应接受适当的化学预防,包括未通过母亲化学预防获得保护的母乳喂养婴儿。对于前往尚未报告氯喹耐药性的地区(即中美洲部分地区、加勒比地区和中东部分地区)旅行,仅使用氯喹就足以进行抗疟疾预防。甲氟喹是对氯喹耐药的恶性疟原虫地区化学预防的首选药物,可用于婴儿和幼儿。氯喹和氯胍的联合用药在儿童中耐受性良好,但对耐药疟疾的效果要差得多。需要进一步研究以确定用于儿童化学预防的抗疟疾药物的最佳剂量方案。